Clinical Trial Update: Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating Ivonescimab with carboplatin and docetaxel in early-stage triple-negative breast cancer is currently recruiting. The sponsor is Cedars…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: TNBC, TNBC - Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING